P636: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES

por Kwiatek, Michal, Subramanian Guru Murthy, Guru, Hoffmann, Marc, Roeker, Lindsey, Tessoulin, Benoit, Danilov, Alexey, Alencar, Alvaro J., Shah, Nirav N., Ghesquieres, Herve, Le Gouill, Steven, Jurczak, Wojciech, R. Mato, Anthony, Patel, Vishalkumar, Guo-Avrutin, Yingying, Pauff, James M., Kazmierczak, Maciej
Publicado 2023